Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joaquin Duato | M | 61 | 35 years | |
| Kathryn Wengel | F | 58 | 36 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alex Gorsky | M | 63 | 35 years | |
| Todd Simpson | M | 63 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 9 years |
| James Johnson | M | 67 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 7 years |
| Michael H. Ullmann | M | 66 | 33 years | |
| John Johnson | M | 66 | 19 years | |
| William Goolsbee | M | 70 | 9 years | |
| David J. Poston | M | 61 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
| Leslie Hudson | M | 76 | 2 years | |
| John C. Hodgman | M | 69 | 11 years | |
| Tom Manion | M | 70 | 8 years | |
| Denis Burger | M | 80 | 16 years | |
| Vartan Gregorian | M | 90 | 13 years | |
| Mary O'Neil Mundinger | M | 87 | 19 years | |
| Ben Price | M | 68 | 9 years | |
| Richard E. Leigh | M | 64 | 1 years | |
| Peter D. O'Hanley | M | 73 | 5 years | |
| Michael Perry | M | 64 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 14 years |
| K. Michael Forrest | M | 80 | 5 years | |
| Scott Stromatt | M | 66 | 5 years | |
| Gerald Ostrov | M | 73 | 15 years | |
| Michelle Harrison | M | - | 3 years | |
| William McComb | M | 61 | 14 years | |
| Mark D. Aaron | M | - |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 years |
| Kevin Mosher | M | - | 4 years | |
| Miguel Patricio | M | 57 | 6 years | |
| Terry Conrad | M | - |
Wyeth Holdings LLC
 Wyeth Holdings LLC Chemicals: AgriculturalProcess Industries Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ. | 8 years |
| Cynthia Shumate | F | 62 | 1 years | |
| Bruce R. York | M | 69 | 1 years | |
| Michael O'Neill | M | 64 | - | |
| Mark Erlander | M | 64 | 6 years | |
| Glenn C. Rice | M | 68 | 5 years | |
| Andrew Maslaveckas | M | - | - | |
| David John Bailey | M | 75 | - | |
| Jack Butler | M | - | 7 years | |
| Chris Calabretta | M | - | 26 years | |
| Angelo Scopelianos | M | 69 | 24 years | |
| Marianne de Backer | M | 55 | 28 years | |
| Janice M. Smiell | M | - | 9 years | |
| Tomas Jan Heyman | M | 68 | 23 years | |
| Patrick W. McNallen | M | - | 2 years | |
| Mike Werner | M | - | 2 years | |
| Andrea J. Casper | F | - | - | |
| Ray Ogle | M | - | - | |
| Manuel Aguero | M | 62 | 6 years | |
| Robert O’Holla | M | 72 | 18 years | |
| Davide Gallotti | M | 65 | 5 years | |
| Christopher J. Stergion | M | 58 | 15 years | |
| Ken Berlin | M | 59 | 13 years | |
| Pierre B. Pirard | M | 56 | 15 years | |
| Robin T. Barney | F | 62 | - | |
| Nevin Grinnell | M | - | 3 years | |
| Thayer White | M | - | 10 years | |
| B. G. Susan Robinson | F | 62 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 11 years |
| Marc Wipperman | M | - | 19 years | |
| Kenneth G. Hayes | M | - | 17 years | |
| David Anderson | M | 71 | 6 years | |
| Arlene Morris | F | 72 | 16 years | |
| Warren E. Hall | M | 71 | 3 years | |
| Maximillian D. Fiore | M | 69 | 4 years | |
| Ivan Delevic | M | 59 | 4 years | |
| Jun Bao | M | 58 | 4 years | |
| David Schubert | M | 57 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 3 years |
| Patrick M. Lonergan | M | 89 | 30 years | |
| Gérard Vaillant | M | 82 | 17 years | |
| Geert Cauwenbergh | M | 70 | 8 years | |
| Paul J. Guagliardo | M | - | 3 years | |
| Arnold G. Langbo | M | 86 | 19 years | |
| Jean-Luc Butel | M | 67 | 6 years | |
| Peter D. Bewley | M | 77 | 17 years | |
| Roger L. Hawley | M | 71 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 5 years |
| Nadav Friedmann | M | 81 | 11 years | |
| James L. Natale | M | 77 | 15 years | |
| James Canfield | M | 66 | 4 years | |
| JoAnn Heffernan Heisen | F | 74 | - | |
| Bill Doyle | M | 61 | 5 years | |
| George A. Ziets | M | 77 | 7 years | |
| John Fluke | M | 81 | 3 years | |
| David M. Clapper | M | 72 | 16 years | |
| Dan Eckert | M | 59 | 2 years | |
| John Finn | M | 68 |
Wyeth Holdings LLC
Wyeth Holdings LLC Chemicals: AgriculturalProcess Industries Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ. | 11 years |
| Ron Hunt | M | 59 | 7 years | |
| John Steven Sonnier | M | - | 7 years | |
| Alan Dunton | M | 70 | 7 years | |
| Bruno A. Melzi | M | 76 | 10 years | |
| Thomas M. Tully | M | 78 | 8 years | |
| Michael A. Zeher | M | 76 | 22 years | |
| Joseph M. Davie | M | 84 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | - |
| Stephen Aselage | M | 73 | 1 years | |
| Gerard N. Burrow | M | - | 12 years | |
| Edward F. Kenney | M | 79 | 5 years | |
| William W. Crouse | M | 80 | - | |
| David E. Collins | M | 89 | 26 years | |
| Mark Adams | M | 62 | 3 years | |
| Mark P. Richmond | M | 92 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 9 years |
| Nelson L. Levy | M | 82 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 11 years |
| Louis P. Lacasse | M | 67 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 8 years |
| Maxine Frank Singer | M | - | 12 years | |
| Per A. Peterson | M | 79 | 13 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jack L. Bowman
- Personal Network
